Articles tagged with Gene Targeting
Researchers developed a nanoparticle that delivers an mRNA vaccine targeting a KRAS antigen, boosting the immune response against pancreatic cancer. Experiments in mice showed inhibited and prevented tumor growth, as well as long-term protection against recurrence.
Researchers at the University of Missouri have identified a small molecule drug that targets a specific serotonin receptor, showing promise as a treatment for sarcopenia. The study suggests that this neurotherapeutic can improve muscle strength by activating motor neurons to fire more effectively.
The Damon Runyon Cancer Research Foundation has named 13 new Fellows, awarding them $300,000 each to investigate cancer causes and mechanisms. Five recipients of the Dale F. Frey Award for Breakthrough Scientists will also receive an additional $100,000 investment to catapult their research careers.
The new AI model leverages hypergraphs to quickly and accurately identify therapeutic gene targets for diseases. HIT outperformed existing models in all tested metrics, demonstrating its accuracy in classifying therapeutic gene targets with great precision.
Researchers are enrolling volunteers for a four-year study that will use advanced imaging, genetics, exercise science, neuroscience, and remote monitoring to investigate age-related health decline. The goal is to help individuals and healthcare practitioners better prevent the impact of disease on older adults.
PARP inhibitors have been found to be effective in treating cancers with BRCA1/2 mutations by blocking DNA repair pathways. The combination of PARPis with chemotherapeutic drugs can also improve treatment efficacy, increasing DNA damage and blocking repair processes.
Researchers discovered that erucamide inhibits Type III Secretion injectisome assembly in Gram-negative bacteria, enhancing plant immunity and reducing disease susceptibility. Exogenous application of erucamide protects crops from bacterial diseases, offering a potential biopesticide for sustainable agriculture.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
A study uncovered new genetic clues explaining why some prostate cancers grow slowly while others become life-threatening, identifying 223 mutations that determine tumor progression. The research shows germline and somatic variability work together to initiate and drive prostate cancer.
CerTracker LLC, a digital credential management platform, aims to streamline compliance and onboarding for healthcare professionals. The company will use the $10,000 grant to reduce administrative burdens and improve workforce efficiency in healthcare settings.
Key molecular applications in diagnosing and managing hematopoietic and lymphocytic neoplasms include comprehensive mutational profiling, aiding accurate diagnosis and prognostication. The use of targeted therapies against specific genetic abnormalities further refines treatment selection.
Rare genetic diseases affect 300 million people globally, with one in three dying before age five. Global collaborations are transforming clinical care by leveraging genomic technologies and evidence-based approaches.
Researchers at VCU Massey Comprehensive Cancer Center have identified an innovative combination treatment strategy that collaborates to kill AML cells. The new approach targets the SRC gene and MCL-1 protein, leading to increased cell death in leukemia cells. This discovery offers a promising new direction for leukemia treatment.
UTA's expansion of its undergraduate research program has enabled students to present their work at major symposiums, including the American Institute of Aeronautics and Astronautics conference. The program has strengthened students' commitment to pursuing graduate studies in various fields.
Researchers at MD Anderson Cancer Center have identified biomarkers for predicting treatment response in metastatic breast cancer and found a potential target for tumor progression in pancreatic cancer. Additionally, they discovered that abnormal chromosome changes predict survival in patients with secondary acute myeloid leukemia.
A new study discovered rare gene variants in Asian Indian people that increase the risk of Type 2 diabetes, providing a window into targeted treatment. The findings suggest that these variants can be used to create personalized medications that target specific proteins or pathways.
Researchers from Yale University and Altos Labs have identified age-invariant genes that stay the same across all tissues during aging. These genes are linked to essential cellular functions, challenging the common belief that gene dysregulation drives aging.
A Japanese version of the Esophageal Hypervigilance and Anxiety Scale has been developed and validated for clinical use in Japan. The scale, which evaluates symptom-specific hypervigilance and anxiety for esophageal symptoms, showed validity comparable to standardized mental and physical health surveys.
A review highlights the potential role of single nucleotide polymorphisms (SNPs) in improving early diagnosis and targeted intervention for coronary microvascular dysfunction. SNPs may influence vascular function, inflammation, and endothelial dysfunction, making them a key factor in disease prognosis and personalized therapy.
Regular psychological health screening during pregnancy and postpartum may improve maternal cardiovascular health outcomes. Integrating comprehensive mental health support into perinatal care is essential to reduce adverse pregnancy outcomes and long-term cardiovascular risks.
Researchers have discovered several novel downstream p53 targets that could lead to improved cancer therapies. The study highlights the critical role of p53 in preventing cancer and identifies two new genes, ALDH3A1 and NECTIN4, as potential targets for cancer treatment.
A new test called EpiAgePublic estimates biological age using only three DNA sites in the ELOVL2 gene, simplifying traditional methods while maintaining accuracy. The study found that EpiAgePublic accurately tracks aging patterns and can identify factors accelerating the aging process.
Researchers discovered noncoding cryptic peptides as an alternative source of target antigens for ovarian cancer. The findings could improve treatment approaches by mobilizing the immune system to attack tumor cells.
Scientists at Nagoya University have developed a new mRNA technology that can produce up to 200 times more protein than traditional methods. This breakthrough enables the creation of healthy proteins to treat illnesses or toxic proteins to kill unwanted cells.
Researchers at UCSF have identified unique, cancer-specific proteins created through mistakes in RNA splicing. These antigens could be used to create potent immunotherapies that recognize and attack hard-to-treat tumors. The discovery offers new hope for glioma patients and expands the number of targets available for cancer therapy.
The Grubhub Community Fund has awarded the American Heart Association a $2 million grant to support food security, technology innovation, and economic resiliency in New York City and Chicago. The funds will be allocated to up to 12 organizations and entrepreneurs focused on improving health equity and expanding access to capital.
Researchers at U of T discover a ginger compound called furanodienone that selectively binds to and regulates nuclear receptor PXR, reducing inflammation in the colon. FDN has been shown to increase tight junction proteins, repairing damage to the gut lining caused by inflammation.
UTA research projects contributed $59 million to the national economy in 2024, supporting student development and collaboration with other research organizations. The university's research infrastructure, including cutting-edge equipment, helped drive economic impact in North Texas and beyond.
A new study published in Annals of Neurology found that lower concentrations of vitamin B12 in healthy, older adults led to signs of neurological and cognitive deficiency. These individuals showed slower processing speeds, brain lesions, and delayed responses to visual stimuli compared to those with higher B12 levels.
The Lung Cancer Research Foundation and Israel Cancer Research Fund are partnering to test an innovative new treatment for lung cancer. The project aims to explore the effects of a drug that targets IGF2BP1, a protein involved in cancer cell growth.
Researchers at Virginia Tech have developed a method to convert gut bacteria into mini protein factories that produce and release sustained flows of targeted proteins within the lower intestine. This approach eliminates a major roadblock in delivering drugs to this part of the body, offering potential treatment for chronic diseases.
Researchers have discovered a new mechanism by which bacteria defend against CRISPR-Cas systems, and how phages counter these defenses. This discovery holds potential to enhance the safety and precision of CRISPR-based technologies.
A team of researchers from the University of Arizona College of Medicine – Tucson found that an FDA-approved osteoporosis treatment, risedronate, can correct a gene mutation and normalize heart function in animal models. The study provides hope for treating other rare diseases using precision treatments tailored to individual mutations.
Researchers successfully developed CoQ10-producing rice through targeted gene editing, offering a cost-effective approach to nutritional fortification. The discovery provides great potential benefit for human health, particularly heart protection, and expands the food sources of CoQ10.
Researchers created a Spanish-language Android app called Impacto to support Hispanic smokers in quitting. The app's pilot test shows promising results, decreasing daily smoking rates and improving cessation rates among participants.
The Damon Runyon-St. Jude Pediatric Cancer Research Fellowship aims to address a funding gap for pediatric cancer research. The program supports innovative projects that could significantly impact the diagnosis or treatment of one or more pediatric cancers.
The Colorectal Cancer Alliance has awarded new grants to researchers, convened top scientists at the Cure CRC Summit, and launched K-SPY, a groundbreaking multi-center platform trial for high-risk colorectal cancer cases. The initiative aims to improve outcomes for millions affected by the disease.
Scientists at Duke University have discovered a master epigenetic switch that can be activated using CRISPR to compensate for missing genes in Prader-Willi syndrome. This approach could potentially treat the disease by turning on naturally suppressed genes from one parent, addressing the underlying genetic defect.
Researchers at Virginia Tech have developed a way to convert gut bacteria into miniature protein factories that produce and release targeted proteins inside the lower intestine. This breakthrough could potentially treat chronic diseases.
A team from Tokyo University of Science developed a novel trivalent platform for triple click chemistry, allowing for the efficient synthesis of complex compounds. The approach utilizes simple initial materials and promotes sustainable pharmaceutical synthesis.
A new study from the University of Pennsylvania School of Medicine has created a comprehensive genetic map of over 1,000 genes influencing kidney function, providing new insights into the causes of kidney disease. The researchers discovered that proximal tubule cells are a key
The American Heart Association and NFL Alumni Association collaborate to promote healthy lifestyles through Life's Essential 8, which includes four indicators of cardiovascular health and four behavioral/lifestyle factors. By following these steps, adults can lower their risk of heart disease, stroke, and other cardiovascular conditions.
Researchers discovered that mismatch repair genes are critical in eliciting damages to neurons vulnerable to Huntington's disease, triggering downstream pathologies and motor impairment. Targeting these genes may offer novel therapeutic approaches, including improving locomotor and gait deficits and reducing neuronal cell death.
New cyanine-carborane salts show promise in eradicating metastatic breast cancer tumors with minimal side effects. The therapy targets specific proteins in cancer cells, allowing for precise killing of diseased cells while sparing healthy tissue.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
A new case report reveals a rare and aggressive form of leukemia developing from donor cells nine years after a stem cell transplant. The disease, driven by genetic mutations in key genes, progresses despite intensive treatment and ultimately proves fatal.
Thousands of proteins rely on their tails to become successfully embedded within the cellular membrane. Researchers discovered a protein called YidC that helps short tails cross the fatty membrane, enabling functional protein-tail integration.
Researchers identified peri-centrosome-localized siRNAs in C. elegans, which accumulate at the centrosome during cell cycle and are essential for development. The study provides new insights into RNAi-mediated gene regulation in C. elegans.
Researchers have created an immune map for pancreatic cancer, showing why some tumours are more susceptible to macrophage-based therapies. The study identifies potential avenues for improved treatment approaches, including boosting certain cell responses and depleting suppressive immune cells.
A new genetic mutation, RUFY1-RET fusion, was discovered in a patient with stage IV CD-74-ROS1 fusion NSCLC who developed resistance to lorlatinib. The finding highlights the importance of ongoing genetic testing to guide therapy decisions.
A large genetic dataset and multi-omics approach identified 58 novel drug targets for both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). The study highlights the importance of developing targeted therapies for both subtypes, which have limited therapeutic options.
Researchers identified a method to enhance CAR-T cell therapy by modifying the CUL5 gene. This approach improves T cells' growth and longevity, making them more effective in fighting cancer. The study suggests a new way to create targeted cells using a virus to deliver genetic material.
The American Heart Association and the National Football League are awarding $1,000 grants to support physical activity in local schools. The grants aim to encourage students to move for at least 60 minutes each day through the NFL PLAY 60 app, available on iOS and Android devices.
Researchers aim to identify key mechanisms and molecular targets to prevent tumor progression in Rhabdomyosarcoma patients. The study focuses on the TAK1 protein, which plays a significant role in regulating cell growth, and its potential inhibition as a therapeutic approach.
Researchers at UCSF have discovered how a unique type of virus called a jumbo phage protects itself inside bacteria. The shield works via a set of secret handshakes that allow only useful proteins to pass through, giving the phage an advantage over regular phages when fighting infections.
Researchers at U of T have developed a new platform called smol-seq that uses DNA sequencing to detect metabolites. This method enables the analysis of hundreds of metabolites simultaneously, making it faster and more precise than current methods.
Researchers discovered that a topical ABT-263 treatment effectively reduces aged skin senescence markers, priming the skin for improved subsequent wound healing. The treatment also triggered inflammation, which surprisingly helped the healing process by 'waking up' the skin's repair systems.
A new drug developed by the Centre for Addiction and Mental Health (CAMH) has shown significant promise in reversing memory loss in a mouse model of Alzheimer's disease. The drug, GL-II-73, selectively targets GABA receptors to restore brain function and repair damaged neural connections.
A new study identified USP5 as an enzyme crucial for breaking down unneeded or damaged proteins in the heart. Low levels of USP5 lead to protein buildup, triggering dilated cardiomyopathy in animal models. Increasing USP5 levels helps clear protein 'junk', improving heart function and reducing disease progression.